Physician profile
Charles Hollander
NPI 1518950799
$1,920.05
in general payments reported to CMS, 2019-2025
10 companies · $492 in 2025
The $492 reported for 2025 was more than what 82% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.48 · 2020: $19.40 · 2021: $299 · 2022: $425 · 2023: $318 · 2024: $329 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $473.92 | 2021-2025 | |
| Abbvie INC. | $398.37 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $291.56 | 2022-2024 | Cequa |
| Alcon Vision LLC | $183.20 | 2019-2025 | Precision 1, Precision7 |
| Allergan, INC. | $153.06 | 2021-2022 | |
| Coopervision INC. | $146.03 | 2022-2025 | Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $138.14 | 2022-2025 | Miebo, Infuse |
| Tarsus Pharmaceuticals, INC. | $78.32 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $38.05 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hollander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.